Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037888 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial

A Phase 4 study of Hip Arthroscopy and Femoracetabular Impingement, sponsored by Henry Ford Health System.

Recruiting
Registry status
Phase 4
Development phase
100
Enrollment target
1
Study location

NCT07037888: Recruiting Phase 4 study of Hip Arthroscopy and Femoracetabular Impingement, sponsored by Henry Ford Health System.

NCT07037888 is a Phase 4 study of Hip Arthroscopy and Femoracetabular Impingement that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 100 participants, below the 1,117-participant average among 10 other Hip Arthroscopy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037888, a Phase 4 study of Hip Arthroscopy and Femoracetabular Impingement, is actively recruiting participants, sponsored by Henry Ford Health System.

RECRUITING
Registry status
Phase 4
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System in Detroit, Michigan. Both men and women are included, and all participants must be able to consent and communicate in English. The main questions it aims to answer are: Can ketorolac help control pain as effectively or better than opioids after hip arthroscopy? Will ketorolac use reduce the amount of opioid medication needed after surgery? Researchers will compare the group receiving ketorolac to the group receiving standard opioid pain medications to see if ketorolac reduces pain and opioid use after surgery. Participants will: Be randomly assigned to one of two groups: The control group, which receives the current standard pain management protocol (hydrocodone-acetaminophen and diazepam) The experimental group, which receives the same protocol plus ketorolac and a stomach-protecting medication (omeprazole) Receive their assigned pain medications after hip arthroscopy Be asked to: Take the prescribed medications after discharge Complete a pain journal for 5 days following surgery, documenting pain levels and any side effects Complete follow-up surveys and assessments at 2 weeks, 6 weeks, and 3 months after surgery The main measurement researchers will use is the Visual Analog Scale (VAS) for pain on post-operative day 4. Additional measures include how many narcotic pills are used and results from PROMIS physical function and pain interference scores. The hope is that ketorolac will provide equal or better pain control without the risks of addiction and side effects associated with opioid medications. If successful, this approach could offer a safer alternative for managing pain after hip arthroscopy. Participants may personally benefit by having effective

Primary Outcome

A validated tool used to help a person rate the intensity of certain sensations and feelings, such as pain. The visual analog scale for pain is a straight line with the far-left end meaning no pain and the far-right end meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels. It may be used to help choose the right dose of pain medicine.

Interventions

  • DRUG Ketorolac
  • DRUG Omeprazole
  • DRUG Control (Standard treatment)

Study Locations (1)

Michigan

  • Henry Ford Health - Detroit

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-12-13
Est. Completion 2026-12
Phase Phase 4
Henry Ford Health System

234 total trials

What NCT07037888 shows while recruiting

NCT07037888 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 1,117-participant average among 10 other Hip Arthroscopy trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Hip Arthroscopy appearing as the primary indexed condition, and to 3 interventions - of which Ketorolac is the first listed.

NCT07037888 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT07037888 about?

NCT07037888 is a clinical study titled "Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial". The goal of this clinical trial is to learn whether the medication ketorolac can help manage pain after hip arthroscopy as well or better than the standard opioid-based pain medications. This study focuses on adult patients (over 18 years old) undergoing hip arthroscopy at Henry Ford Health System i...

What is the current status of trial NCT07037888?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2023-12-13. Estimated completion is 2026-12.

What conditions does trial NCT07037888 study?

This clinical trial studies the following conditions: Hip Arthroscopy, Femoracetabular Impingement.

What interventions are being tested in trial NCT07037888?

The interventions under investigation include: Ketorolac (DRUG), Omeprazole (DRUG), Control (Standard treatment) (DRUG).

Who is sponsoring clinical trial NCT07037888?

This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037888 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Arthroscopy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07037888's enrollment target sits among peer trials

100 6th of 10 higher than 3 of 10 other Hip Arthroscopy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hip Arthroscopy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07037888, the US trial registry maintained by the National Library of Medicine. NCT07037888 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.